Connect patients with treatments
What we commit to
We will continue to work closely with healthcare providers, patient organisations and regulatory authorities to make our therapies available to those who can benefit from them, connecting efforts to break down geographic, economic and social barriers.
We commit to streamlining access to treatments, including exploring and collaborating with healthcare providers to ensure timely and efficient delivery of therapies.
What we have done so far
Sobi works with communities to increase Patient Access through the established healthcare system. In some countries, Sobi has managed access programmes for people living with life-threatening disease with no other option available. Sobi has an established process for emergency orders within the EU and the US for life-saving medicines, which are also available during non-office hours 365 days a year for immediate service if needed to save a patient’s life.
Through long-standing partnerships with other companies, Sobi has successfully commercialised a generation of extended half-life products for Haemophilia in Europe, the Middle East and North Africa. These treatments are meant to bring benefit for people with this rare bleeding disorder. Sobi also supports people living with Rare Diseases and healthcare providers in navigating reimbursement processes in markets where access may be limited.
In 2025, Sobi’s access programmes impacted
19
Countries, while reimbursement was achieved for different products in 22 Countries
Measurement
We will measure impact through:
- Number of countries impacted by managed access programmes
- Number of managed access programmes in place
- Number of countries impacted by successful reimbursement
- Number of products available through managed access programmes
Involvement
The Sobi departments involved are:
- Value and Access
- Patient Engagement
- Medical
- Compliance
- Legal (depending on project)
Definition: A Managed Access Programme (MAP) is a mechanism that allows patients with serious or life threatening rare diseases to gain access to Sobi medicines (outside of their approved indications or before commercial availability), when no satisfactory alternative treatment options exist. These programmes are typically considered when:
- The patient has a condition with high unmet medical need.
- The medicine shows potential clinical benefit based on available evidence.
- Regulatory approval or commercial supply is not yet established in the patient’s country
MAPs follow local laws and need an HCP request.